bysi20240208

0001171843-24-004980.txt : 20240829 0001171843-24-004980.hdr.sgml : 20240829 20240829163020 ACCESSION NUMBER: 0001171843-24-004980 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240829 DATE AS OF CHANGE: 20240829 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeyondSpring Inc. CENTRAL INDEX KEY: 0001677940 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38024 FILM NUMBER: 241264162 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR STREET 2: SUITE 410 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 646-528-4184 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR STREET 2: SUITE 410 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 6-K 1 bysi20240208_6k.htm FORM 6-K bysi20240208_6k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2024

Commission File Number: 001-38024

BeyondSpring Inc.

BeyondSpring Inc.
100 Campus Drive, West Side, 4th Floor, Suite 410
Florham Park, New Jersey 07932
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On August 29, 2024, BeyondSpring Inc. (the “Company”) reported financial results for the six months ended June 30, 2024.

This Report on Form 6-K is incorporated by reference into the Registration Statement on Form F-3, File No. 333-280153, and the Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082, of the Company.

BEYONDSPRING INC.

CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND JUNE 30, 2024

(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)

	December 31, 2023			June 30, 2024
	$			$
				(Unaudited)
Assets
Current assets:
Cash and cash equivalents		7,809			8,397
Restricted Cash		9,941			-
Short-term investments		193			5,963
Advances to suppliers		306			280
Prepaid expenses and other current assets		170			279
Total current assets		18,419			14,919

Noncurrent assets:
Property and equipment, net		1,628			1,487
Operating lease right-of-use assets		4,397			4,050
Other noncurrent assets		364			441
Total noncurrent assets		6,389			5,978

Total assets		24,808			20,897

Liabilities and equity

Current liabilities:
Accounts payable		1,407			2,119
Accrued expenses		2,581			1,772
Current portion of operating lease liabilities		631			656
Deferred revenue		1,751			2,001
Other current liabilities		1,588			1,639
Total current liabilities		7,958			8,187

Noncurrent liabilities:
Operating lease liabilities		3,364			3,030
Deferred revenue		33,242			32,343
Other noncurrent liabilities		3,705			3,612
Total noncurrent liabilities		40,311			38,985

Total liabilities		48,269			47,172

Commitments and contingencies

Mezzanine equity
Contingently redeemable noncontrolling interests		11,874			12,274

Shareholder's deficit
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,015,476 and 40,300,350 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively)		4			4
Additional paid-in capital		368,599			372,117
Accumulated deficit		(396,302	)		(403,564	)
Accumulated other comprehensive income		894			1,258

Total BeyondSpring Inc.’s shareholders’ deficit		(26,805	)		(30,185	)
Noncontrolling interests		(8,530	)		(8,364	)
Total shareholders' deficit		(35,335	)		(38,549	)

Total liabilities, mezzanine equity and shareholders' deficit		24,808			20,897

BEYONDSPRING INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2024

(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)

	Six months ended June 30,
	2023			2024
	$			$

Revenue		875			1,000

Operating expenses
Research and development		(9,214	)		(4,149	)
General and administrative		(5,145	)		(4,273	)

Loss from operations		(13,484	)		(7,422	)
Foreign exchange loss, net		(200	)		(83	)
Interest income		281			46
Other income, net		133			82

Loss before income tax		(13,270	)		(7,377	)
Income tax benefits		9			-

Net loss		(13,261	)		(7,377	)
Less: Net loss attributable to noncontrolling interests		(541	)		(115	)
Net loss attributable to BeyondSpring Inc.		(12,720	)		(7,262	)

Net loss per share
Basic and diluted		(0.33	)		(0.19	)

Weighted-average shares outstanding
Basic and diluted		38,976,761			39,070,994

Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustment		1,249			576
Unrealized holding loss		(5	)		-
Comprehensive loss		(12,017	)		(6,801	)
Less: Comprehensive gain (loss) attributable to noncontrolling interests		(84	)		97
Comprehensive loss attributable to BeyondSpring Inc.		(11,933	)		(6,898	)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BeyondSpring Inc.


	By:	/s/ Lan Huang
	Name: Lan Huang
	Title: Chairperson and Chief Executive Officer

Date: August 29, 2024

EXHIBIT INDEX

Exhibit No.	Exhibit

101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

EX-101.SCH 2 bysi-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2023 and 2024 link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 3 bysi-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 4 bysi-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bysi-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Notes To Financial Statements Notes To Financial Statements [Abstract] Note To Financial Statement Details Textual us-gaap_IncomeTaxExpenseBenefit Income tax benefits Noncurrent liabilities: Equity Components [Axis] Equity Component [Domain] Unrealized holding loss Other noncurrent assets us-gaap_LiabilitiesCurrent Total current liabilities Other current liabilities us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income tax Operating expenses Foreign currency translation adjustment Cash and cash equivalents us-gaap_AssetsCurrent Total current assets Noncurrent assets: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total shareholders' deficit Advances to suppliers Amendment Flag Other comprehensive loss, net of tax of nil: Accounting Policies [Abstract] us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss attributable to BeyondSpring Inc. Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,015,476 and 40,300,350 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively) Entity Interactive Data Current Common Stock, Shares Authorized (in shares) Common Stock, Shares Authorized (in shares) Common Stock, Shares, Outstanding (in shares) Deferred revenue Common Stock, Shares, Issued (in shares) Common Stock, Par or Stated Value Per Share (in dollars per share) Current Fiscal Year End Date Accrued expenses Document Fiscal Period Focus Document Fiscal Year Focus Accounts payable dei_DocumentPeriodEndDate Document Period End Date dei_EntityFileNumber Entity File Number Entity Emerging Growth Company dei_DocumentType Document Type Entity Small Business Entity Shell Company us-gaap_PolicyTextBlockAbstract Accounting Policies Document Information [Line Items] Document Information [Table] Entity Public Float Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Revenue Foreign exchange loss, net Basic and diluted (in shares) Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name Current liabilities: Entity [Domain] Legal Entity [Axis] Statement [Table] dei_EntityAddressAddressLine1 Entity Address, Address Line One Statement of Financial Position [Abstract] us-gaap_Assets Total assets dei_EntityAddressCityOrTown Entity Address, City or Town dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code Noncontrolling interests Basic and diluted (in dollars per share) dei_EntityAddressStateOrProvince Entity Address, State or Province Weighted-average shares outstanding Statement [Line Items] Income Statement [Abstract] Additional paid-in capital Short-term investments Shareholder's deficit Other income, net Restricted Cash Current assets: us-gaap_NetIncomeLoss Net loss attributable to BeyondSpring Inc. Contingently redeemable noncontrolling interests us-gaap_TableTextBlock Notes Tables Interest income us-gaap_Liabilities Total liabilities Less: Net loss attributable to noncontrolling interests Commitments and Contingencies Mezzanine equity us-gaap_OperatingIncomeLoss Loss from operations Prepaid expenses and other current assets us-gaap_SellingGeneralAndAdministrativeExpense General and administrative us-gaap_LiabilitiesNoncurrent Total noncurrent liabilities Other noncurrent liabilities Less: Comprehensive gain (loss) attributable to noncontrolling interests Property and equipment, net us-gaap_LiabilitiesAndStockholdersEquity Total liabilities, mezzanine equity and shareholders' deficit Accumulated deficit us-gaap_ResearchAndDevelopmentExpense Research and development us-gaap_AssetsNoncurrent Total noncurrent assets Accumulated other comprehensive income Deferred revenue us-gaap_ContractWithCustomerLiabilityNoncurrent us-gaap_StockholdersEquity Total BeyondSpring Inc.’s shareholders’ deficit us-gaap_ProfitLoss Net loss us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive loss us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Operating lease liabilities Class of Stock [Axis] Current portion of operating lease liabilities Operating lease right-of-use assets Net loss per share EX-101.PRE 6 bysi-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2024
Document Information [Line Items]
Document Type	6-K
Entity File Number	001-38024
Entity Registrant Name	BeyondSpring Inc
Entity Address, Address Line One	100 Campus Drive, West Side, 4th Floor, Suite 410
Entity Address, City or Town	Florham Park
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07932
Document Period End Date	Jun. 30, 2024
Entity Central Index Key	0001677940
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 9 R2.htm IDEA: XBRL DOCUMENT

Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 8,397	$ 7,809
Restricted Cash	0	9,941
Short-term investments	5,963	193
Advances to suppliers	280	306
Prepaid expenses and other current assets	279	170
Total current assets	14,919	18,419
Noncurrent assets:
Property and equipment, net	1,487	1,628
Operating lease right-of-use assets	4,050	4,397
Other noncurrent assets	441	364
Total noncurrent assets	5,978	6,389
Total assets	20,897	24,808
Current liabilities:
Accounts payable	2,119	1,407
Accrued expenses	1,772	2,581
Current portion of operating lease liabilities	656	631
Deferred revenue	2,001	1,751
Other current liabilities	1,639	1,588
Total current liabilities	8,187	7,958
Noncurrent liabilities:
Operating lease liabilities	3,030	3,364
Deferred revenue	32,343	33,242
Other noncurrent liabilities	3,612	3,705
Total noncurrent liabilities	38,985	40,311
Total liabilities	47,172	48,269
Commitments and Contingencies
Mezzanine equity
Contingently redeemable noncontrolling interests	12,274	11,874
Shareholder's deficit
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,015,476 and 40,300,350 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively)	4	4
Additional paid-in capital	372,117	368,599
Accumulated deficit	(403,564)	(396,302)
Accumulated other comprehensive income	1,258	894
Total BeyondSpring Inc.’s shareholders’ deficit	(30,185)	(26,805)
Noncontrolling interests	(8,364)	(8,530)
Total shareholders' deficit	(38,549)	(35,335)
Total liabilities, mezzanine equity and shareholders' deficit	$ 20,897	$ 24,808

XML 10 R3.htm IDEA: XBRL DOCUMENT

Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares)	500,000,000	500,000,000
Common Stock, Shares Authorized (in shares)	500,000,000	500,000,000
Common Stock, Shares, Issued (in shares)	40,300,350	39,015,476
Common Stock, Shares, Outstanding (in shares)	40,300,350	39,015,476

XML 11 R4.htm IDEA: XBRL DOCUMENT

Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2023 and 2024 - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 1,000	$ 875
Operating expenses
Research and development	(4,149)	(9,214)
General and administrative	(4,273)	(5,145)
Loss from operations	(7,422)	(13,484)
Foreign exchange loss, net	(83)	(200)
Interest income	46	281
Other income, net	82	133
Loss before income tax	(7,377)	(13,270)
Income tax benefits	0	9
Net loss	(7,377)	(13,261)
Less: Net loss attributable to noncontrolling interests	(115)	(541)
Net loss attributable to BeyondSpring Inc.	$ (7,262)	$ (12,720)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.19)	$ (0.33)
Weighted-average shares outstanding
Basic and diluted (in shares)	39,070,994	38,976,761
Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustment	$ 576	$ 1,249
Unrealized holding loss	0	(5)
Comprehensive loss	(6,801)	(12,017)
Less: Comprehensive gain (loss) attributable to noncontrolling interests	97	(84)
Comprehensive loss attributable to BeyondSpring Inc.	$ (6,898)	$ (11,933)

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,B#'5D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #(@QU9O<-A7N\ K @ $0 &1O8U!R;W!S+V-O&ULS9++ M3L,P$$5_!7F?C),@'E::#557("%1"<3.LJ>M1?R0/2CIW^.$-A6"#V#IF>LS M9Z1I51#*1WR./F D@^EJM+U+0H45.Q % 9#4 :U,94ZXW-SY:"7E9]Q#D.I# M[A%JSF_ (DDM2<($+,)"9%VKE5 1)?EXPFNUX,-G[&>85H ]6G24H"HK8-TT M,1S'OH4+8((11IN^"Z@7XES]$SMW@)V28S)+:AB&GQY=YW<*X M1-(IS+^2$70,N&+GR:_-PWJ[85W-Z^N"WQ7U_;;FHN&"W[Y/KC_\+L+6:[,S M_]CX+-BU\.LNNB]02P,$% @ R(,=69E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #(@QU9PD=02'$# #K"P & 'AL+W=O3N4AJNO6D[]Z#8"];$EGR2',*W M[\H&0SN.0EYL2=;^]=N5O-KA1NDGDP)8\I)GTHR"U-KB.@Q-G$+.S;DJ0.*7 ME=(YM]C5Z] 4&GA2&>59&%':#W,N9# >5F,+/1ZJTF9"PD(34^8YU]LI9&HS M"EBP'W@0Z]2Z@7 \+/@:EF#_*!8:>V&CDH@>4\ M.O/(#I)-O7<;B\@<6FLRG?& M2) +6;_YRRX01P87]!6#:&<05=SU0A7E#;=\/-1J0[2;C6JN4;E:62.]*>4ZZ](Q$-.IY]+J-Q]U*K_N6QT=NDG^^ MX"QR:R$W/]I\KB5[[9+NS[DV!8]A%."O84 _0S#^Y0/KTU\]P+T&N.=3/P!_ MVQ;0!NR N&H@+K\KN:,Q%!N2^S!]!MY'X-2AEG>ZE?Q?[#4__%)X' M6 MC-3%S/:7)-[5IS0I^-034*<_)@NLG#]Q5 W?U+KBEY>@XTBVT>A8R;HVQ7_+^ MSL/%Z"&=TG>1+92Q/"-_BX+,5-+*]88B'5QU(Q_;4:IGIR62!6BA7+I/"%X: M[5!^J28IOY65672@BTZ)W P!-4;L%J^/%_(9MJUT?BF*F:8_&%SU?#\".UP8 MS)O>Q[-2:Q>VN3 QDOT%7/MCYY?K=%C4Z3(?VN%J8"?>#<=LV M\G!7,'^B_S_5[KR]SN67^]U[_ \W!O.G^@DB)356QM>M''Z!%<\,M*&$1_57 M#GI=59F&Q*J4MB[%FM&FDIW4]=MA>ET&?^5Z+:0A&:S0E)X/,#2ZKBSKCE5% M5&PO=V]R:W-H965T&ULM5G;;MLX$/T5 MPBUZ >)8)'5M$@-IBL5V@5[0M+O/C,3$1"51)2FGZ=@,R9ESACJ_Y^*[7%&JP,^JK.7%;*54\V:QD/F*5D2>\H;6^I=;+BJB]*VX M6\A&4%)T@ZIR@8(@7E2$U;/E>??LLUB>\U:5K*:?!9!M51'Q\):6_/YB!F>/ M#[ZPNY4R#Q;+\X;-(X?FR=SOIWFH&[UX_> M_^B"U\'<$$FO>/D/*]3J8I;.0$%O25NJ+_S^3[H-*#+^+5=K!&4+%Z\Y?\W$[$S@ 83@Q VP'HV %X.P!W@6Z0=6&](XHLSP6_!\)8 M:V_FHIN;;K2.AM5F&:^5T+\R/4XM+]N"*5J *UY+7K*"F)NWI"1U3L%UMY&( M!/P6O*,YK6ZH !B> !0@#$A=@&\UV3IX7RLJ6&4<%7J5CW'Y5UM3@(/.70CF MX-OU._#J^6OP'+ :?%WQ5NI7R/.%TG$:M(M\&]/;34QH(B;M][3WZQA^Y1^N M(SWMH]P?OM"SVT\QZJ<8=?[PA+^K5@A:FZ E5?*-*YZ-@]#MP&3R&]F0G%[, M=*I**M9TMGSQ#,;!F2NZ)W*V%RON8\4^[\LK(E?=QLC-!?W1LC4I=?#.5=RX MBCI7IMRLERG.DO/%>C<:VRA)@ZPWVD,9]BA#+\HO5"K!\F[?:YPN;!L'\C=*QU-HV^ @=N-+>GR)%]]G01O""D!_ M-J8*R6XS'RUCVE&7LB9SMA0N#@1:# _M(*R6A'KK]8^I8 M8U+Q!-14.0DI<*Q-.JYE+JL8I>ZE@3L4#KU8/VFD1+'Z#I14*QH@C'29\]MY MJV^FM]/6ZRZ:,(C&.>JRVJW2^Y@'3H1>&EI^ZE*R'F\K)TYD(]@IM%N8MA&. MPPF4 YM!/YUM,O,XE-A1D9-T#-.VBG$ZD9QPX#/H)[0-3@\XFZQ0D%IBA >8,L]YJ]D;-.2! MW)34&;"#):%5T1U6, RF4G!@2NBG2@U0M'2@2B= %]TE: S009Q1.J&%X$"+ MT,^+C]NFT:+(M'RZ9>"C4K>SHYSP;3*,HWB,WF&$I\ /A F]!*6[B%NJX1>Z MUUW3NG4O?^9(R\ J;;853*()@&A@..1GN$][HNC 1"(7<^'Q1G591>E$^4 # MOR$_O^WKHT-(;;Y*H<7$#JLDBZ:0[G1Z_E9O1R8=JG7H:7N^_Z/I0P-/(C]/ MCA7(H36R61 '>*P\7%:3G(X&KD1^KCPF,9%-A!CA<-Q?N%6Q3>_?]1]7O#;)1>M\"J_7 MGSO]@;.._ ='A^O(0)K(WV9^H+]^D5H_[%HN]>",]4F[S*?RMG]:-I P]I-P MO[*J?- %J:"T,EJQ2R?]D^!E::HJ,X>K5$XG@=9N6NT+L"9E2\] % 0GP>;?HQEIU8H+]HL69P!G)P&,3L(D[I(\ M#$ZP-L91;\RD-/J\.\%JE53ZPFP&WWG\WI'ZB=Y1LJ'=AY+RX;5S31R]]7C? M^$SV9V_GE-BO%RZ+@AE)KRNQ.:V;LQKDI&&Z,CM!.H1 HOLDZZC881>G4391 MC_$@&;!?,NA.J:W:LON0X=O@MAR8:\Z*8FM*'88XBW$PH1SPH!RP7SGL(MV> M>O)*)\#*?'A;4UU(]+U3\F#'83&*QN<7#JLTF]H.@X3 QTB(M_2!U\5U(\PF M?U_GIR^>I0@F9W*3#YL2([M@2X- ;V:XR/OU.] M;0TQ3[&]95QF$9XX><:#U,#'G#WO3O!+[]3:O?(%*\:J[7%&B41L#_?LMY^KQQGSO[;_O+_\%4$L#!!0 M ( ,B#'5ETD8)>H ( *H' 8 >&PO=V]R:W-H965T&ULM951;]HP%(7_RE6TAU;JB$D"W2I :JFF==(T5-3NV2078M6QF>V4;;]^ MUTX:00LKG30>P';N.3G?3;!'&VT>;(GHX&8D5MSV]1D57 MEMI4W-'4K&*[-LB+(*IDG# VC"LN5#09A;69F8QT[:10.#-@ZZKBYM<52KT9 M1_WH:>%6K$KG%^+):,U7.$=WMYX9FL6=2R$J5%9H!0:7X^BR?S$=^OI0<"]P M8[?&X$D66C_XR4TQCI@/A!)SYQTX_3SB%*7T1A3C1^L9=;?TPNWQD_NGP$XL M"VYQJN5W4;AR''V(H, EKZ6[U9O/V/(,O%^NI0W?L&EK601Y;9VN6C$EJ(1J M?OG/M@];@GYV0)"T@N180=H*T@#:) M8U]SQR\C&67VJ%D+)@E\')C!M4KD0G1[N MZ?^OCQ/68XSU1_'C-NJK93M(:8>4O@$I1+=P6;M2&_&;L#Q&\_3V9F_,AUNA M!JS]/(M_3.4.0=819/^3(#N:X)C*'8)!1S!X,\$9W%A;OQY_\")4QE+&TL'S M]"\+TX^L/\C.A_O##[OPPW\(_ZUVUM'>(M3J-8+AL00O"P\0Q%L[J3_%OG*S M$LJ"Q"5)6>^<>F&:DZ&9.+T.F^M".]JJP["DPQ2-+Z#K2ZW=T\3OU]WQ//D# M4$L#!!0 ( ,B#'5D:(.R85P4 "85 8 >&PO=V]R:W-H965T&ULK5C;6#5)]USIA!CV4A]/4L-V9W-9_K M-&SU;)Z]D&MEG)O"B[8 M!X7TOBRI^G+#"OEP/<.SXX./?)L;^V"^6N[HEMTR<[?[H.!NWEK)>,F$YE(@ MQ3;7LU?X:DT65J&2^).S!]V[1M:5>RD_VYLWV?7,LXA8P5)C35#X.[ U*PIK M"7#\W1B=M6M:Q?[UT?HOE?/@S#W5;"V+3SPS^?4LGJ&,;>B^,!_EPV^L<:@" MF,I"5[_HH9'U9BC=:R/+1AD0E%S4__2Q"41/ >RX%4BC0(8*P8B"WRCXE:,U MLLJMU]30U5+)!Z2L-%BS%U5L*FWPA@N;QENCX"T'/;.Z$W2?<<,R]$88IGB) MUE)DD"9X E=:%CRC]O6M@3_(G]%(;N!5"563VW0>&'HKM4904LCD#-WR1_1. M"I-K]#-8RM#O>\&0[[U$Q",^HB*S%P&Z0'>WK]&+[W]808./"LOU[=GX#CMTGQ*WO!B+V/[,#$ MGKD"4RLN*D6[10\K['G>B"*;=L1[K2.YJRZQD4CV;JP&:K'[[#H?>3*^;/9.S$W47K[N*)#&A& M59I7Y9I!.@JYL\7O.A_EUR&#?'X'78SK\= W>,^ IUH!$ACXZ,6)'&?I1-(3I$,,^B48R MC$F'E#R1XR,ZP"O8AAOG9FFL]-#'TQ"&U",;\Z.@'3_//J XQ)L>RBO"34^^Q=JAQ7ZF60:!/\&+*Y<39)+/OS6% MSV7M-!@=O9-I>C^.;^E>*2;2+P@F8:$+6I\69'_!M_38!-]8[C?"130%W6RCY$J>YGN'R,7(Z$XZPB?3A+\^*S G M.@>GA[&'APA=U$\\'(V@[*B?? WUGV+=4MC%+RSB'__7+$#.63X9SC0.F8NQ M3Q+2#0)D>A XC_U_&PF(@^O#.(F'3KA& IRQ[51UQ#9[?X*MU?637F:E/$-]1M>5"HX)MP*1W&0$H51_*U3=&[JIS MK7MIC"RKRYS1C"DK .\W4IKCC5V@/1I=_0M02P,$% @ R(,=6?7>IUD- M P C1 T !X;"]S='EL97,N>&ULW5AM:]LP$/XKQAVCA5''\>K%:QS8 M H7!.@KMAWTK2BP[ EGR9*5+^NNGDQSGI;K2]<.6S:&Q=(_NN4=WY\ATW.HU MI[<+2G6PJKEH\W"A=?,QBMKY@M:D/9<-%08II:J)-E-516VC*"E:<*IY-!P, MTJ@F3(23L5C65[5N@[E<"IV'26\*W.U+D8=Q^CX,'-U4%C0/[T_?_EA*??DF M3=RO$"TO.!N5!FBV+TZ MW<#0SBGGM]#:W\L][E6Y4]4!U%3T0R.H&SH:-P'^73;'O4.;O8HV:-B#U)^7 M9C?"SJ%7Z(VB)5O9^:KLXV/L,*!*L_FNY: _@ MVZ#!;,FX9J*;+5A14/'DZ##TFLS,N]8>OUE?T)(LN;[KP3S!&9BHW04.A\B5O?P(YN,P/P(8 M%@=3@/DX+RS._[2?$;H?AV':1EYDA/J,4!_GY4.F]H/%\?MDYO+O-,N2)$VQ MC$ZG7@53+&]I"G]^-DP;>&!Q(-+OY1JO-MXAS_, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+ MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D M5XA-/E_G;@ M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 ( ,B#'5FEV^-.BP$ "L$ / >&PO=V]R:V)O;VLN M>&ULQ9-O:]PP#,:_BO$':*[IK;"C.>BN^W,PMM+K^K;X8J41M>5@*[VUG[YR MTK# X-B;LE>V'@GYIP?YXA#BXSZ$1_7;.TJ5;IF[55&DN@5OTDGH@"33A.@- M2Q@?BM1%,#:U .Q=42X6YX4W2'I],?6ZCL4\" PU8R 1LW"'<$A_\CE43YAP MCP[YN=+#W8%6'@D]OH"M]$*KU(;#MQ#Q)1 ;MZMC<*[2IV/B#B)C_9>\RY"W M9I\&A2M0E6?696$Q2 M6QI;26V>5)[>VG%J%MR9AW&%DHA;.X"_'^1E;Y'!JHWHP:$U.?ADG*$:U*Z= M099'(,O_"'E?SB#/CD">O2_D+S)OF%N2]4.?<2U0&L%GD,LCD,MA3Z?EM- @ M@?TA#R31Y:/4UU'E8UB;[ JP, !H !X;"]?PS&01\2+/()+;8Z (EBAH4"KK MC^7W7S$^G'%0W#M+7>])C&:P5,J.V>\!2'=H%*V<1QMO&A>,XAA#"U[IJVH1 MLO5Z!^&3(8^'3Z:H)X^_$%W3]!I/3M\,6OX"AKL+5^H068I:A1:YE# .\YC@ M=6Q6D2Q%=2EEJ"X;"4L+98E0MKQ0G@CERPL5B5#Q1R'B:4":;=XYJ=_^L9[C M6YS;7_$]3+=V]W2 Y&\>'U!+ P04 " #(@QU9CK"GUB21]W_]C'N_?-7U_];A56:7?DR_Y]77T" M4$L! A0#% @ R(,=60=!36*! L0 ! ( ! M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " #(@QU9O<-A7N\ K @ M$0 @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 M" #(@QU9F5R<(Q & "<)P $P @ '- 0 >&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( ,B#'5G"1U!(<0, .L+ 8 M " @0X( !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ R(,=6721@EZ@ @ J@< !@ M ("!]A( 'AL+W=O&PO !?&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " #(@QU9CK"GUB XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 4 68 1 false 0 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 Sheet http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024 Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 Statements 2 false false R3.htm 002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 (Parentheticals) Sheet http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2023 and 2024 Sheet http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2023 and 2024 Statements 4 false false All Reports Book All Reports bysi-20240630.xsd bysi-20240630_cal.xml bysi-20240630_def.xml bysi-20240630_lab.xml bysi-20240630_pre.xml bysi20240208_6k.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bysi20240208_6k.htm": { "nsprefix": "bysi", "nsuri": "http://www.beyondspringpharma.com/20240630", "dts": { "schema": { "local": [ "bysi-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bysi-20240630_cal.xml" ] }, "definitionLink": { "local": [ "bysi-20240630_def.xml" ] }, "labelLink": { "local": [ "bysi-20240630_lab.xml" ] }, "presentationLink": { "local": [ "bysi-20240630_pre.xml" ] }, "inline": { "local": [ "bysi20240208_6k.htm" ] } }, "keyStandard": 68, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 4, "entityCount": 1, "segmentCount": 0, "elementCount": 94, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 110, "http://xbrl.sec.gov/dei/2024": 13 }, "report": { "R1": { "role": "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024", "longName": "001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024", "shortName": "Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals", "longName": "002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 (Parentheticals)", "shortName": "Audited Consolidated Balance Sheet as of December 31, 2023 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2024 (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024", "longName": "003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2023 and 2024", "shortName": "Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2023 and 2024", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20240208_6k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19", "r276" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r5", "r6", "r33", "r67", "r191", "r209", "r210" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r28", "r276", "r303" ] }, "us-gaap_AdvancesOnInventoryPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvancesOnInventoryPurchases", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Advances to suppliers", "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r285" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r45", "r56", "r66", "r82", "r104", "r106", "r112", "r113", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r152", "r156", "r167", "r188", "r236", "r271", "r272", "r276", "r280", "r297", "r298", "r300" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r62", "r68", "r82", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r152", "r156", "r167", "r276", "r297", "r298", "r300" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total noncurrent assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r82", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r152", "r156", "r167", "r297", "r298", "r300" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Noncurrent assets:" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r8", "r64", "r267" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r25", "r46", "r189", "r223" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r27", "r224" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r3", "r27", "r224", "r242", "r304", "r305" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,015,476 and 40,300,350 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively)", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r27", "r190", "r276" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss attributable to BeyondSpring Inc.", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r72", "r74", "r79", "r184", "r201", "r203" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss, net of tax of nil:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Less: Comprehensive gain (loss) attributable to noncontrolling interests", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r15", "r18", "r72", "r74", "r78", "r183", "r201", "r202" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r43", "r72", "r74", "r77", "r182", "r201" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r133", "r134", "r137" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "us-gaap_ContractWithCustomerLiabilityNoncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r133", "r134", "r137" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Net loss per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r80", "r88", "r89", "r90", "r91", "r92", "r93", "r97", "r98", "r100", "r101", "r102", "r103", "r147", "r150", "r165", "r166", "r185", "r204", "r268" ] }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Weighted-average shares outstanding" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r281" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024", "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals", "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information", "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r281" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r282" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r281" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r281" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r281" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss, net", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r259" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income tax", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r34", "r51", "r55", "r186", "r196", "r270", "r271", "r291", "r292", "r293", "r294", "r295" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax benefits", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r57", "r58", "r95", "r96", "r104", "r110", "r113", "r139", "r140", "r143", "r205", "r273" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r104", "r109", "r113", "r271", "r288" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024", "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals", "http://www.beyondspringpharma.com/20240630/role/statement-document-and-entity-information", "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r4", "r20", "r21", "r22", "r23", "r24", "r25", "r26", "r82", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r153", "r156", "r157", "r167", "r222", "r269", "r280", "r297", "r300", "r301" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities, mezzanine equity and shareholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r32", "r48", "r194", "r276", "r290", "r296", "r299" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r22", "r63", "r82", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r153", "r156", "r157", "r167", "r276", "r297", "r300", "r301" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total noncurrent liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r23", "r24", "r25", "r26", "r82", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r153", "r156", "r157", "r167", "r297", "r300", "r301" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Noncurrent liabilities:" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r31", "r47", "r82", "r119", "r123", "r125", "r126", "r127", "r130", "r131", "r167", "r193", "r226" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLoss", "totalLabel": "Net loss attributable to BeyondSpring Inc.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r35", "r38", "r52", "r61", "r71", "r73", "r76", "r82", "r86", "r88", "r89", "r90", "r91", "r92", "r95", "r96", "r99", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r147", "r150", "r166", "r167", "r199", "r244", "r260", "r261", "r278", "r297" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Less: Net loss attributable to noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r17", "r44", "r71", "r73", "r92", "r95", "r96", "r198", "r287" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r55", "r270", "r291", "r292", "r293", "r294", "r295" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r178" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r178" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r177" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Other noncurrent assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r65" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r0", "r200" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Unrealized holding loss", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r69", "r70", "r118" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r21", "r276" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r24" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r286" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProfitLoss", "totalLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r61", "r71", "r73", "r81", "r82", "r86", "r92", "r95", "r96", "r119", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r147", "r150", "r151", "r154", "r155", "r166", "r167", "r186", "r197", "r214", "r244", "r260", "r261", "r274", "r275", "r279", "r287", "r297" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r2", "r179", "r187", "r195", "r276" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Contingently redeemable noncontrolling interests", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r11", "r12", "r40", "r41" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_ResearchAndDevelopmentExpense", "negatedLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r138", "r266", "r271", "r302" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r284", "r289" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r29", "r42", "r192", "r208", "r210", "r212", "r225", "r276" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r53", "r54", "r104", "r107", "r108", "r111", "r113", "r114", "r115", "r116", "r135", "r136", "r181" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_SellingGeneralAndAdministrativeExpense", "negatedLabel": "General and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r49", "r50", "r285" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024", "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals", "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r83", "r84", "r85", "r105", "r176", "r181", "r211", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r262", "r277" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024", "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024-parentheticals", "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r83", "r84", "r85", "r105", "r117", "r176", "r181", "r211", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r262", "r277" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total BeyondSpring Inc.\u2019s shareholders\u2019 deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r27", "r30", "r31", "r39", "r226", "r242", "r263", "r264", "r276", "r280", "r290", "r296", "r299", "r304" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Shareholder's deficit" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Total shareholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r13", "r14", "r16", "r59", "r60", "r75", "r83", "r84", "r85", "r87", "r92", "r94", "r120", "r121", "r122", "r132", "r141", "r142", "r144", "r145", "r146", "r148", "r149", "r150", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r172", "r173", "r174", "r175", "r180", "r206", "r207", "r213", "r226", "r242", "r263", "r264", "r265", "r279", "r290", "r296", "r299", "r304" ] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityAbstract", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2023-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2024" ], "lang": { "en-us": { "role": { "label": "Mezzanine equity" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "presentation": [ "http://www.beyondspringpharma.com/20240630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2023-and-2024" ], "lang": { "en-us": { "role": { "label": "Basic and diluted (in shares)", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r9", "r10" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 19 0001171843-24-004980-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-004980-xbrl.zip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end XML 20 bysi20240208_6k_htm.xml IDEA: XBRL DOCUMENT 0001677940 2024-01-01 2024-06-30 0001677940 2023-01-01 2023-06-30 0001677940 2024-06-30 0001677940 2023-12-31 iso4217:USD shares iso4217:USD shares thunderdome:item Q2 2024 --12-31 false 0001677940 6-K 001-38024 BeyondSpring Inc 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park NJ 07932 2024-06-30 7809000 8397000 9941000 0 193000 5963000 306000 280000 170000 279000 18419000 14919000 1628000 1487000 4397000 4050000 364000 441000 6389000 5978000 24808000 20897000 1407000 2119000 2581000 1772000 631000 656000 1751000 2001000 1588000 1639000 7958000 8187000 3364000 3030000 33242000 32343000 3705000 3612000 40311000 38985000 48269000 47172000 11874000 12274000 0.0001 0.0001 500000000 500000000 39015476 39015476 40300350 40300350 4000 4000 368599000 372117000 -396302000 -403564000 894000 1258000 -26805000 -30185000 -8530000 -8364000 -35335000 -38549000 24808000 20897000 875 1000 9214 4149 5145 4273 -13484 -7422 -200 -83 281 46 133 82 -13270 -7377 -9 -0 -13261 -7377 -541 -115 -12720 -7262 -0.33 -0.19 38976761 39070994 1249 576 -5 0 -12017 -6801 -84 97 -11933 -6898